HLVX
HilleVax, Inc.2.0900
+0.0000+0%
Sep 16, 4:00:01 PM EDT
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
104.76MP/E (TTM)
-Basic EPS (TTM)
-1.44Dividend Yield
0%Recent Filings
8-K
HilleVax merger finalized
HilleVax completed its merger with XOMA Royalty Corporation's subsidiary on September 17, 2025, after a tender offer secured 77.48% of shares at $1.95 cash per share plus a contingent value right. The deal shifts control to XOMA, delisting HilleVax from Nasdaq and ending public trading. Board and executives departed; the firm now operates privately. Shareholders eye CVR payouts.
10-Q
Q2 FY2025 results
HilleVax trimmed its Q2 FY2025 operating loss to $7.0M, down sharply from $43.0M a year earlier, as research and development costs plunged 95% y/y to $1.3M following the discontinuation of HIL-214 infant trials and workforce cuts. Net loss narrowed to $5.3M, or $(0.11) per diluted share on 50.1M weighted shares, versus $40.7M or $(0.83) last year; the gap reflects lower stock-based comp and no impairment charges this quarter. Cash burn eased, with $159.5M in cash and marketable securities at quarter-end after repaying $28.5M in debt, bolstering liquidity through at least 12 months amid strategic reviews. A pending merger with XOMA Royalty offers $1.95 cash per share plus a contingent value right, yet regulatory hurdles in vaccine development loom large.
8-K
HilleVax merger with XOMA Royalty
HilleVax announced a definitive merger agreement on August 4, 2025, with XOMA Royalty Corporation to acquire all outstanding shares for $1.95 in cash per share plus a non-transferable CVR for potential future payments. The tender offer starts by August 18, 2025, with closure expected in September 2025, subject to customary conditions. This deal caps the clinical-stage vaccine developer's operations amid sharply reduced R&D expenses to $3.3 million for the first half of 2025 from $52.6 million last year, yielding a net loss of $11.3 million versus $87.5 million prior. Yet risks loom if closing conditions falter.
8-K
HilleVax acquisition by XOMA
HilleVax agreed to be acquired by XOMA Royalty on August 4, 2025, via a tender offer for all shares at $1.95 cash plus a non-transferable CVR tied to excess cash over $102.95 million, lease savings, and 90% of norovirus program proceeds if sold within two years post-close. The board unanimously approved the deal, securing 22.9% stockholder support, with closure eyed for September 2025 absent financing hurdles. Termination risks a $2.475 million fee if HilleVax pursues a superior bid.
8-K
Annual meeting elects directors
HilleVax stockholders elected Robert Hershberg, Jeryl Hilleman, and Aditya Kohli as Class III directors for three-year terms at the June 23, 2025, annual meeting. Votes for each exceeded 22 million, with withholdings under 2 million and 14.5 million broker non-votes. The board stays stable. Ernst & Young LLP's appointment as auditors for fiscal 2025 passed overwhelmingly, with 38.2 million for versus just 133,000 against.
BVAXD
BioVaxys Technology Corp.
0.15-0.03
DVAX
Dynavax Technologies Corporatio
10.78-0.07
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
LSB
LakeShore Biopharma Co., Ltd
0.63+0.00
MRNA
Moderna, Inc.
29.89-0.03
NVAX
Novavax, Inc.
6.54-0.04
PCVX
Vaxcyte, Inc.
43.67-0.67
VIR
Vir Biotechnology, Inc.
6.48-0.24
VXRT
Vaxart, Inc.
0.37+0.01
XOMA
XOMA Royalty Corporation
25.83+0.34